You’ve got that coveted accelerated regulatory pathway. Now what?
Summary: While everyone wants a Breakthrough Therapy Designation (BTD), Fast Track or PRIME, these designations also add to the pressure of getting a drug to the clinic under tight timelines.
In this webcast, John Carrol, Founder and Editor of EndPoints News speaks with industry veterans from Alnylam Pharma, Urogen Pharma, Mirum Pharmaceuticals, and Catalent biologics about the pitfalls present in any accelerated development challenge, and how to avoid them.
Watch the webinar to get expert insights on successfully navigating accelerated development programs.